← Eichor
Condition: 5 Aminolevulinic Acid Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: 5 Aminolevulinic Acid

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The IMmunotherapy Pleural 5-ALA PDT
Phase 2 · 1 location(s) · University Hospital, Lille · NCT04400539An Open-Label, Two-Cohort, Pharmacokinetic Study in a Maximal Use Setting for Patients With Actinic Keratosis on the Upp
Phase 1 · 1 location(s) · Sun Pharmaceutical Industries Limited · NCT07729579Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery
NA · 1 location(s) · University of Illinois at Chicago · NCT07111182Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Phase 3 · 10 location(s) · Sun Pharmaceutical Industries, Inc. · NCT07144345Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Di
Phase 2 · 11 location(s) · Alpheus Medical, Inc. · NCT07225621Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P
EARLY_Phase 1 · 1 location(s) · Mayo Clinic · NCT07076472Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
Phase 1/Phase 2 · 1 location(s) · Universität Münster · NCT05590689Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery
NA · 3 location(s) · Kuopio University Hospital · NCT06740097Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
Phase 2 · 1 location(s) · Henry Ford Health System · NCT06948552Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence i
Phase 2 · 2 location(s) · michal roll · NCT01898416Fluorescence Enhanced Stereotactic Surgery (FESS)
Phase N/A · 1 location(s) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT07286903Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk
NA · 1 location(s) · First Affiliated Hospital of Wenzhou Medical University · NCT06052033Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Phase 3 · 11 location(s) · NX Development Corp · NCT05804370Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases
NA · 1 location(s) · Sklifosovsky Institute of Emergency Care · NCT05474573Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
Phase 2 · 1 location(s) · The Center for Clinical and Cosmetic Research · NCT06577311Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescen
Phase 3 · 2 location(s) · Lee's Pharmaceutical Limited · NCT06160492Sonodynamic Therapy in Patients With Recurrent GBM
Phase 1 · 1 location(s) · Shayan Moosa, MD · NCT06039709Loupe-Based Intraoperative Fluorescence Imaging
Phase N/A · 1 location(s) · Guoqiang Yu · NCT04780009Surgical Suction Aspirates Fluorescence Measurement
Phase N/A · 1 location(s) · Kuopio University Hospital · NCT06736470Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Phase 3 · 20 location(s) · Sun Pharmaceutical Industries, Inc. · NCT07144852Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach
Phase N/A · 1 location(s) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT07420543
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.